Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
With a market cap of 132.51B, Vertex Pharmaceuticals(VRTX) trades at $524.12. The stock has a price-to-earnings ratio of 31.40.
On 2026-07-08, Vertex Pharmaceuticals(VRTX) stock traded between a low of $524.12 and a high of $524.12. Shares are currently priced at $524.12, which is 0.0% above the low and 0.0% below the high.
Vertex Pharmaceuticals(VRTX) shares are trading with a volume of 2.66K, against a daily average of 2.39M.
In the last year, Vertex Pharmaceuticals(VRTX) shares hit a 52-week high of $533.67 and a 52-week low of $362.50.
In the last year, Vertex Pharmaceuticals(VRTX) shares hit a 52-week high of $533.67 and a 52-week low of $362.50.
VRTX News
Key Points Crinetics' Palsonify was FDA-approved late last year. The company's atumelnant is currently in late Phase 3 clinical testing. 10 stocks we like be...
Key Points Vertex agreed to buy Crinetics for $85 per share in cash, about $10 billion in equity value. The deal adds a newly launched acromegaly drug and a l...
Jefferies downgraded Crinetics (CRNX) to Hold from Buy with a price target of $85, up from $55, after the company announced it will be acquired by Vertex Pharma...
Analyst ratings
79%
of 33 ratingsMore VRTX News
Vertex expects to finance the acquisition using a combination of cash on hand and debt, supported by $4.5 billion of fully committed bridge financing. Vertex’s...
Analyst Whitney Ijem from Canaccord Genuity maintained a Hold rating on Vertex Pharmaceuticals and keeping the price target at $436.00. Unlock powerful investi...
Biotech and Pharma This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal In this article CRNX VRTX SPX Vertex Pharmaceuticals said late Monday...
Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...
Crinetics Pharmaceuticals (CRNX) stock surged nearly 100% in pre-market trading on Tuesday after Vertex Pharmaceuticals (VRTX) agreed to acquire the biotech com...
Earlier this month, Vertex Pharmaceuticals reported U.S. FDA approval to expand use of its CRISPR-based gene therapy CASGEVY to children as young as two with si...
Risk-on sentiment resurfaced following the long holiday weekend as large-cap growth areas of the market handily outperformed SMIDs and value. Comms Services, Te...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.